Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC
NCT02312557Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Nov 2014
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in castration-resistant prostate cancer (CRPC), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Prostate-Specific Antigen Response. Started Nov 2014; status: completed.
02
Drugs
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02312557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02312557.